From toxic precursors to safe drugs / Mechanisms and relevance of idiosyncratic drug reactions

Arzneimittel-Forschung/Drug Research

Volumn 52, Issue 6, 2002, Pages 423-429

  Petersen, Karl Uwe ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Adverse effects; Cytochrome P450; Drug development; Drug metabolism; Hepatotoxicity; Idiosyncrasy (drug reactions)

Indexed keywords

ACID HALIDE; AROMATIC AMINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUDESONIDE; CAPTOPRIL; CHOLINESTERASE INHIBITOR; CYCLOPHOSPHAMIDE; CYTOCHROME P450; DICLOFENAC; DRUG METABOLITE; GLUTATHIONE; HALOTHANE; HYDROXYLAMINE; ISONIAZID; LIVER ENZYME; NOMIFENSINE; PARACETAMOL; PHENOL DERIVATIVE; PHENYTOIN; PIOGLITAZONE; PRACTOLOL; QUINONE DERIVATIVE; REMOXIPRIDE; RIFAMPICIN; ROSIGLITAZONE; SUXAMETHONIUM; TACRINE; TROGLITAZONE; UNINDEXED DRUG; VALPROIC ACID;

ALZHEIMER DISEASE; CELL DEATH; CELL FUNCTION; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG STRUCTURE; DRUG TRANSFORMATION; GENETIC PREDISPOSITION; HUMAN; IMMUNITY; LIVER TOXICITY; MACROMOLECULE; MOLECULAR RECOGNITION; NONHUMAN; ORTHOSTATIC HYPOTENSION; PRECURSOR; PROTEIN EXPRESSION; REVIEW; RISK FACTOR;

EID: 0036286423     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1299909     Document Type: Review

References (30)

1. Adverse drug reactions
2. General aspects of drug-induced liver disease
3. Immunotoxicology of the liver: Adverse reactions to drugs
4. Drug-induced hepatotoxicity
5. Advances in molecular toxicology - Towards understanding idiosyncratic drug toxicity
6. Hepatotoxicity of non-narcotic analgesics
7. The role of active metabolites in drug toxicity
8. Extrahepatic metabolism of drugs in humans
9. Idiosyncratic drug reactions. Metabolic bioactivation as a pathogenic mechanism
10. Elucidation of mitochondrial effects by tetrahydroaminoacridine (tactine) in rat, dog, monkey and human hepatic parenchymal cells
11. Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tactine hepatotoxicity
12. Cytotoxicity study of tactine, structurally and pharmacologically related compounds using rat hepatocytes
13. Cholinesterase inhibitors in the treatment of Alzheimer's disease: A comparison of tolerability and pharmacology
14. Carcinogenicity of "Alderlin" (pronethalol) in mice
15. Untoward effects associated with practolol administration: Oculomucocutaneous syndrome
16. Side effects and contraindications of beta-receptor blocking agents
17. Immune reactions associated with practolol therapy
18. Practolol metabolism. III. Irreversible binding of [14C]practolol metabolite(s) to mammalian liver microsomes
19. Metabolites of procainamide and practolol inhibit complement components C3 and C4
20. Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission
21. In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: Comparison with pioglitazone and rosiglitazone
22. No reduction of alpha-tocopherol quinone by glutathione in rat liver microsomes
23. Phenytoin metabolism by human cytochrome P450: Involvement of P450 3A and 2C forms in secondary metabolism and drug-protein adduct formation
24. Two types of nomifensine-induced immune haemolytic anaemias: Drug-dependent sensitization and/or autoimmunization
25. Caspase-dependent and -independent mechanisms in apoptosis induced by hydroquinone and catechol metabolites of remoxipride in HL- 60 cells
26. Diclofenac toxicity to hepatocytes: A role for drug metabolism in cell toxicity
27. Differential activation of cyclophosphamide and ifosfamide by cytochromes P- 450 2B and 3A in human liver microsomes